REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
Claude calling Anthropic's S-1 insightful is zero surprise. Like it was ever going to call its own maker's filing boring.